• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday

    6/24/24 1:18:39 PM ET
    $BBIO
    $COIN
    $CYRX
    $DNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $BBIO alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.

    Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly.

    Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral.

    ResMed shares dipped 10.4% to $184.35 on Monday.

    Here are some other big stocks recording gains in today’s session.

    • Molecular Partners AG (NASDAQ:MOLN) shares dipped 22.6% to $7.43.
    • Cryoport, Inc. (NASDAQ:CYRX) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) dipped 19.2% to $22.11.
    • BitFuFu Inc. (NASDAQ:FUFU) fell 17.7% to $5.11. Shares of crypto stocks traded lower after Bitcon fell below $62,000.
    • Inspire Medical Systems, Inc. (NYSE:INSP) declined 15% to $136.88. Stifel analyst Jonathan Block maintained Inspire Medical Systems with a Hold and lowered the price target from $210 to $170.
    • Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) fell 13% to $0.3661.
    • MicroStrategy Incorporated (NASDAQ:MSTR) dipped 10.3% to $1,328.74 after Bitcon fell below $62,000.
    • Paymentus Holdings, Inc. (NYSE:PAY) fell 9.3% to $16.97.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) fell 8.5% to $827.94.
    • Sirius XM Holdings Inc. (NASDAQ:SIRI) fell 8% to $2.6950. Evercore ISI Group upgraded the stock from Underperform to In-Line but lowered its price target from $4.25 to $3.25.
    • Coinbase Global, Inc. (NASDAQ:COIN) dipped 7.7% to $208.51 after the price of Bitcoin fell below $62,000.
    • NVIDIA Corporation (NASDAQ:NVDA) fell 5.8% to $119.11. The stock may be pulling back after recent momentum.

    Now Read This: McDonald’s, Alphabet And 2 Other Stocks Insiders Are Selling

    Get the next $BBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBIO
    $COIN
    $CYRX
    $DNA

    CompanyDatePrice TargetRatingAnalyst
    Paymentus Holdings Inc.
    $PAY
    2/20/2026$35.00Outperform → Strong Buy
    Raymond James
    Inspire Medical Systems Inc.
    $INSP
    2/13/2026Outperform → Peer Perform
    Wolfe Research
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$74.00Outperform → Neutral
    Robert W. Baird
    Inspire Medical Systems Inc.
    $INSP
    2/12/2026$70.00Overweight → Equal Weight
    Wells Fargo
    SiriusXM Holdings Inc.
    $SIRI
    2/10/2026$24.00Underweight → Neutral
    Analyst
    SiriusXM Holdings Inc.
    $SIRI
    2/6/2026Buy → Neutral
    Seaport Research Partners
    Coinbase Global Inc.
    $COIN
    1/28/2026$240.00Neutral
    Robert W. Baird
    More analyst ratings

    $BBIO
    $COIN
    $CYRX
    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liaw Yih-Shyan Wally converted options into 3,400 shares and covered exercise/tax liability with 1,220 shares, increasing direct ownership by 2% to 94,492 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:27:31 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    SVP, Chief Accounting Officer Cheung Kenneth converted options into 2,250 shares and covered exercise/tax liability with 927 shares, increasing direct ownership by 2% to 58,530 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:26:52 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Director Liu Liang Chiu-Chu Sara converted options into 3,650 shares and covered exercise/tax liability with 2,108 shares, increasing direct ownership by 0.25% to 609,800 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:26:04 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $BBIO
    $COIN
    $CYRX
    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BridgeBio to Participate in March Investor Conferences

    PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in the following healthcare investor conferences: TD Cowen 46th Annual Healthcare Conference, Boston, MA: Fireside Chat on Monday, March 2 at 3:50 pm ESTLeerink Partners Global Healthcare Conference, Miami, FL: Fireside Chat on Tuesday, March 10 at 1:00 pm EDTBarclays 28th Annual Global Healthcare Conference, Miami FL: Fireside Chat on Wednesday, March 11 at 12:30 pm EDT To access the live webcast of BridgeBio's prese

    2/23/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a

    2/19/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

    Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costsBOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", )) and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chem

    2/18/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBIO
    $COIN
    $CYRX
    $DNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $BBIO
    $COIN
    $CYRX
    $DNA
    SEC Filings

    View All

    SEC Form 144 filed by BridgeBio Pharma Inc.

    144 - BridgeBio Pharma, Inc. (0001743881) (Subject)

    2/19/26 4:22:37 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

    SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    2/17/26 8:46:59 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    2/17/26 5:00:26 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $COIN
    $CYRX
    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Paymentus upgraded by Raymond James with a new price target

    Raymond James upgraded Paymentus from Outperform to Strong Buy and set a new price target of $35.00

    2/20/26 8:05:33 AM ET
    $PAY
    Real Estate

    Inspire Medical Systems downgraded by Wolfe Research

    Wolfe Research downgraded Inspire Medical Systems from Outperform to Peer Perform

    2/13/26 8:29:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Coinbase Global downgraded by Monness Crespi & Hardt with a new price target

    Monness Crespi & Hardt downgraded Coinbase Global from Buy to Neutral and set a new price target of $120.00

    2/12/26 7:44:13 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    $BBIO
    $COIN
    $CYRX
    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Curet Myriam bought $804 worth of shares (5 units at $160.72) and sold $616 worth of shares (6 units at $102.59), decreasing direct ownership by 0.03% to 3,365 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    11/24/25 8:40:17 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Director Briger Peter L Jr bought $19,800,000 worth of Series A Perpetual Stretch Preferred Stock (220,000 units at $90.00) (SEC Form 4)

    4 - MICROSTRATEGY Inc (0001050446) (Issuer)

    7/29/25 6:20:52 PM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    President & CEO Le Phong bought $495,000 worth of Series A Perpetual Stretch Preferred Stock (5,500 units at $90.00) (SEC Form 4)

    4 - MICROSTRATEGY Inc (0001050446) (Issuer)

    7/29/25 4:55:28 PM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    $BBIO
    $COIN
    $CYRX
    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    SiriusXM Appoints Eve Konstan as Executive Vice President, Chief Legal Officer and Secretary

    NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Sirius XM Holdings Inc. (NASDAQ:SIRI) today announced the appointment of Eve Konstan as Executive Vice President, Chief Legal Officer and Secretary, effective February 9, 2026. Konstan succeeds Richard N. Baer, who is retiring. Konstan is a distinguished legal mind known for her expertise in media, entertainment, and communications law, with an extensive background advising top companies. Most recently, Konstan served as General Counsel at Spotify Technology S.A, where she supported the organization across all legal matters, including co

    1/29/26 8:00:00 AM ET
    $SIRI
    Broadcasting
    Consumer Discretionary

    Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance

    MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 Revenue Revenue for the fourth quarter of 2025 is anticipate

    1/12/26 6:45:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    BitFuFu to Update Investors at the Emerging Growth Conference on December 11, 2025

    SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BitFuFu Inc. ("BitFuFu" or the "Company") (NASDAQ:FUFU), a world-leading Bitcoin miner and mining services innovator, today announced that it will provide a brief update to investors at the Emerging Growth Conference on December 11, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Vice President of Investor Relations, Charley Brady, who will present an update and, time permitting, open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event. BitFuFu will be presenti

    12/9/25 11:00:00 AM ET
    $FUFU
    Finance: Consumer Services
    Finance

    $BBIO
    $COIN
    $CYRX
    $DNA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a

    2/19/26 8:00:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

    PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentat

    2/17/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    $COIN
    $CYRX
    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paymentus Holdings Inc.

    SC 13G - Paymentus Holdings, Inc. (0001841156) (Subject)

    12/10/24 5:08:45 PM ET
    $PAY
    Real Estate

    SEC Form SC 13G filed by MicroStrategy Incorporated

    SC 13G - MICROSTRATEGY Inc (0001050446) (Subject)

    11/14/24 6:24:12 PM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Coinbase Global Inc.

    SC 13G/A - Coinbase Global, Inc. (0001679788) (Subject)

    11/14/24 5:44:24 PM ET
    $COIN
    Finance: Consumer Services
    Finance